Inhibition of Mcl-1 has emerged as a promising strategy for thetreatment of human cancers by restoring function in the intrinsicapoptotic pathway, which has often become dysregulated in cancer.Several new compounds have recently entered clinical trials; however,to date there is no approved therapy for Mcl-1 inhibition. The gene discussed is MCL1; the disease is cancer.